Article Text

Download PDFPDF
CP-125 Evaluation of compliance and tolerability in treatment-naÏve patients suffering from idiopathic pulmonary fibrosis (IPF) and treated with pirfenidone
  1. F Capano1,
  2. C Lerda2,
  3. G Bandelli3,
  4. A Filieri1,
  5. C Albera3,
  6. D Ielo1
  1. 1A. O. U San Luigi Gonzaga, Pharmacy, Orbassano TO, Italy
  2. 2University of Turin, School of Hospital Pharmacy, Turin, Italy
  3. 3University of Turin, School of Medicine, Turin, Italy


Background Idiopathic pulmonary fibrosis (IPF) is a rare disease with significant morbidity and mortality, with a 18.07/1,00,000 prevalence in our Region. Pirfenidone is an orally administered antifibrotic approved for the treatment of mild-to-moderate IPF.1 Pirfenidone is generally well tolerated, the most common side effects being on the gastro-intestinal (GI) tract and photosensitivity. However, side effects may partly offset treatment benefits and reduce compliance.

Purpose To assess side effects (tolerability) and compliance in (treatment-naïve) IPF patients receiving pirfenidone.

Material and methods In this prospective observational study, adherence was examined in patients treated between September 2013 and September 2014. Side effects and treatment compliance were recorded in a database. Adherence data were compared with the incidence of side effects occurring in the studied population.

Results 34 IPF patients were evaluated during a 12 month follow-up.

Abstract CP-125 Table 1

Comparison between prescribing and dispensing data showed that 19 (56%) of patients received 100% of the prescribed treatment, 22 (65%) received more than 90%, and only 3 (9%) received less than 50%.

Abstract CP-125 Table 2

Side effects led to only 15% of patients discontinuing pirfenidone and were more evident during the first six months of treatment, as observed in clinical trials.

Conclusion Tolerability: most side effects were manageable with supportive measures.

Compliance: overall it was good. Closer pharmacist/physician interaction could further improve patient compliance.

References and/or Acknowledgements 1 EMA summary of product characteristics

No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.